title: Survival in 86 patients, aged 15-60, with primary acute myelogenous leukemia, treated with a common program in the Norwegian health regions I, III, IV and V in the period 1990-1995.
abstract: Eighty-six patients between 15 and 60 yr with primary acute myelogenous leukemia in health regions I, III, IV and V in Norway were treated according to a common protocol from 21 January 1990 until 1 September 1995 (until 1 January 1993 for health region IV). Seventy-one percent of the patients reached complete remission (CR) and went on to receive consolidation treatment. In addition to chemotherapy, 18 patients under the age of 52, i.e. 28% of all patients in this age group, received allogeneic bone marrow transplantation. A follow-up analysis was performed by 1 September 1996. The median overall survival was 15 months, estimated 3-yr survival 30% and estimated survival at 5 yr was 26%. The median duration of 1st CR was 19 months, and the leukemia-free survival at 3 yr was 29%. At follow-up 26/86 patients were alive, 18 in 1st CR (4 after BMT) and 8 in 2nd CR (5 after BMT in 2nd, 1 after BMT in early 1st relapse). These results are comparable to many previously published studies, but may be inferior to the results obtained with more intensive consolidation treatment, including high dose Ara C.
authors.affiliation: Department of Hematology, Medical clinic, Ullevål University Hospital,Oslo, Norway.
authors.forename: J M
authors.initials: JM
authors.lastname: Tangen
authors.forename: M
authors.initials: M
authors.lastname: Abdelnoor
authors.forename: L
authors.initials: L
authors.lastname: Brinch
authors.forename: I M
authors.initials: IM
authors.lastname: Dahl
authors.forename: J
authors.initials: J
authors.lastname: Lamvik
authors.forename: B
authors.initials: B
authors.lastname: Ly
authors.forename: I
authors.initials: I
authors.lastname: Nesthus
authors.forename: F
authors.initials: F
authors.lastname: Wisløff
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D016026:Bone Marrow Transplantation; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009664:Norway; D016019:Survival Analysis; D014182:Transplantation, Autologous